Stem Cell Therapy receives FDA Boost to enter the US Market – Labiotech.eu (blog)
|
Stem Cell Therapy receives FDA Boost to enter the US Market
Labiotech.eu (blog) TiGenix has received positive feedback from the FDA on an improved global phase III trial protocol for its lead candidate Cx601 for Crohn's disease. This is expected to speed up US approval. TiGenix is a Belgian company developing stem cell therapies. |
